At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 131 enrolled
Drug / intervention
BMS-986165 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects With Moderate to Severe Ulcerative Colitis
In Brief
A Phase 2 clinical trial evaluating BMS-986165 and Placebo for Ulcerative Colitis. Completed, enrolled 131 participants across 107 sites in 13 countries.
Detailed Summary
The purpose of this study is to assess the safety and efficacy of oral deucravacitinib in participants with moderate to severe ulcerative colitis (UC).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUlcerative Colitis
CountriesAustralia, Belgium, Czechia, France, Germany, Hungary, Italy, Japan, Poland, Russia, South Korea, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedMay 2019
Enrollment StartJul 2019
Primary CompletionJun 2021
Study CompletionApr 2023
TodayJul 2026
First PostedMay 1, 2019
Enrollment StartJul 1, 2019
Primary CompletionJun 13, 2021
Study CompletionApr 4, 2023
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 7.2 years ago
Interventions
BMS-986165drug
Specified Dose on Specified Days
Placeboother
Specified Dose on Specified Days